BRPI1008936A2 - método in vitro para detectar pré-disposição, diagnóstico e /ou prognóstico de fibrose e método de seleção de um composto terapêutico - Google Patents

método in vitro para detectar pré-disposição, diagnóstico e /ou prognóstico de fibrose e método de seleção de um composto terapêutico

Info

Publication number
BRPI1008936A2
BRPI1008936A2 BRPI1008936A BRPI1008936A BRPI1008936A2 BR PI1008936 A2 BRPI1008936 A2 BR PI1008936A2 BR PI1008936 A BRPI1008936 A BR PI1008936A BR PI1008936 A BRPI1008936 A BR PI1008936A BR PI1008936 A2 BRPI1008936 A2 BR PI1008936A2
Authority
BR
Brazil
Prior art keywords
predisposition
prognosis
diagnosis
selecting
therapeutic compound
Prior art date
Application number
BRPI1008936A
Other languages
English (en)
Inventor
Alain Dessein
Christophe Chevillard
Violaine Arnaud
Original Assignee
Inserm Inst Nat De La Santé Et De La Rech Médicale
Univ Aix Marseille Ii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inserm Inst Nat De La Santé Et De La Rech Médicale, Univ Aix Marseille Ii filed Critical Inserm Inst Nat De La Santé Et De La Rech Médicale
Publication of BRPI1008936A2 publication Critical patent/BRPI1008936A2/pt
Publication of BRPI1008936B1 publication Critical patent/BRPI1008936B1/pt
Publication of BRPI1008936B8 publication Critical patent/BRPI1008936B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1008936A 2009-02-19 2010-02-18 método in vitro para detectar pré-disposição para ou diagnóstico e/ou prognóstico de fibrose hepática ou cirrose ocorrendo em um indivíduo humano BRPI1008936B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09305159A EP2221387A1 (en) 2009-02-19 2009-02-19 Fibrosis susceptibility gene and uses thereof
EP093051597 2009-02-19
PCT/EP2010/052048 WO2010094740A1 (en) 2009-02-19 2010-02-18 Fibrosis susceptibility gene and uses thereof

Publications (3)

Publication Number Publication Date
BRPI1008936A2 true BRPI1008936A2 (pt) 2016-10-11
BRPI1008936B1 BRPI1008936B1 (pt) 2021-04-06
BRPI1008936B8 BRPI1008936B8 (pt) 2021-07-27

Family

ID=40568438

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008936A BRPI1008936B8 (pt) 2009-02-19 2010-02-18 método in vitro para detectar pré-disposição para ou diagnóstico e/ou prognóstico de fibrose hepática ou cirrose ocorrendo em um indivíduo humano

Country Status (8)

Country Link
US (2) US9297044B2 (pt)
EP (2) EP2221387A1 (pt)
JP (2) JP5837825B2 (pt)
KR (1) KR101748679B1 (pt)
CN (2) CN105907843A (pt)
BR (1) BRPI1008936B8 (pt)
CA (1) CA2752802C (pt)
WO (1) WO2010094740A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012085217A1 (en) * 2010-12-22 2012-06-28 Universite De La Mediterranee (Aix-Marseille Ii) A diagnostic method for dementias
DK2739748T3 (da) * 2011-08-05 2019-06-24 Univ Aix Marseille Il22ra2-gen med fibrosefølsomhed og anvendelser deraf
ES2422874B1 (es) * 2012-03-12 2014-07-15 Universidad Autnoma De Madrid Método in vitro de pronóstico de fibrosis hepática grave
DK3607065T3 (da) * 2017-04-06 2023-06-19 Complete Omics Int Inc Fremgangsmåde og kit til konstruktion af nukleinsyrebibliotek
EP3425056A1 (en) * 2017-07-07 2019-01-09 Genepred Biotechnologies Method for prognosing fibrosis progression
EP3633474B1 (en) * 2018-10-02 2022-04-06 Tetra Laval Holdings & Finance S.A. A system for controlling a manufacturing process for packaging units
WO2020074727A1 (en) 2018-10-11 2020-04-16 Genepred Biotechnologies Method for detecting fibrosis especially keloid
CN111073884A (zh) * 2020-02-14 2020-04-28 昆明理工大学 提高非编码区域距离<50bp的SNP中具有功能效应的SNP位点检测准确率的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770209A (en) * 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
AU8126694A (en) 1993-10-26 1995-05-22 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
CN1589403B (zh) * 2001-09-18 2011-06-01 法布罗根股份有限公司 测定结缔组织生长因子的方法
US7405274B2 (en) * 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
GB0326780D0 (en) * 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
CA2708004C (en) * 2006-12-04 2015-12-01 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
US20130203054A1 (en) 2010-05-04 2013-08-08 Universite D'aix-Marseille Antiviral treatment susceptibility gene and uses thereof
DK2739748T3 (da) 2011-08-05 2019-06-24 Univ Aix Marseille Il22ra2-gen med fibrosefølsomhed og anvendelser deraf

Also Published As

Publication number Publication date
CN102325904A (zh) 2012-01-18
EP2398911B1 (en) 2017-10-18
EP2398911A1 (en) 2011-12-28
JP2016047045A (ja) 2016-04-07
US20160230232A1 (en) 2016-08-11
BRPI1008936B1 (pt) 2021-04-06
CA2752802C (en) 2018-04-03
WO2010094740A1 (en) 2010-08-26
CA2752802A1 (en) 2010-08-26
US9297044B2 (en) 2016-03-29
JP5837825B2 (ja) 2015-12-24
BRPI1008936B8 (pt) 2021-07-27
CN102325904B (zh) 2016-03-30
JP2012524520A (ja) 2012-10-18
US20120135403A1 (en) 2012-05-31
KR20120004971A (ko) 2012-01-13
CN105907843A (zh) 2016-08-31
KR101748679B1 (ko) 2017-07-03
EP2221387A1 (en) 2010-08-25

Similar Documents

Publication Publication Date Title
BRPI1008936A2 (pt) método in vitro para detectar pré-disposição, diagnóstico e /ou prognóstico de fibrose e método de seleção de um composto terapêutico
IL246042A0 (en) Methods and systems for evaluating clinical expenses
IL219210A0 (en) Biomarkers and methods for measuring and monitoring inflammatory disease activity
NO20085322L (no) Fremgangsmate for raskere ansiktsdeteksjon
BRPI0923748A2 (pt) Método para a preparação de dióis
BRPI0815725A2 (pt) Métodos para detecção de oligonucleotídeos
ZA201102070B (en) Method for evaluation,design and optimization of in-situ bioconversion processes
BRPI0822112A8 (pt) sensor, método para detecção e método para produzir um sensor
DK2368118T3 (da) Biomarkører til inhibitorer med anti-angiogen aktivitet
BRPI1015922A2 (pt) sistemas e métodos para testar analitos
BR112012018103A2 (pt) método para detectar a presença de uma amostra de testemunhagem dentro de uma ferramenta de testemunhagem, método para perfurar dentro de um poço com uma ferramenta de testemunhagem, e método para detectar a presença de uma amostra de testemunhagem dentro de uma ferramenta de testemunhagem
EP2142217A4 (en) PCSK9 DETECTION METHOD SECRETED, SELF-GENERATED
BR112013011984A2 (pt) composto, composição farmacêutica, e, métodos para fabricar um composto, para formação de imagem e para detectar agregados tau in vitro e/ou in vivo
HUE051130T2 (hu) Eljárások szimmetrikus dimetilarginin kimutatására
BRPI0911371A2 (pt) método de determinação do prognóstico de funcionamento de um sistema
BR112012014678A2 (pt) "uso do dna mrna, método para o diagnóstico da rosácea e método de monitoramento"
IL248334A0 (en) A method for the detection, quantification and mapping of damage and/or repair of DNA strands
EP2628005A4 (en) BIOMARKERS AND METHOD FOR DETECTING A CHRONIC INFLAMMATORY DISEASE
BRPI0918744A2 (pt) Metodo para produção de açúcar
BRPI0924560A2 (pt) Métodos e kits para detectar, diagnosticar e monitorar doenças
GB2481002B (en) Determining layer thickness
FR2945060B1 (fr) Cassette pour revetement de facade, ensemble et revetement de facade correspondants
BRPI0912766A2 (pt) método de diagnóstico de rolete
ZA201204405B (en) Assay for quantifying neurotoxin
FI20116061A (fi) Entsyymi, jolla on alfa-glukuronidaasiaktiivisuutta

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA REC

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/04/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/02/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO